Skip to Content

News & Events

Press Releases

Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJul 26, 2006	Vertex Pharmaceuticals Reports Second Quarter 2006 Financial Results - VX-950 Global Phase 2b Clinical Development Plan On Track -<br> - Collaboration with Janssen Pharmaceutica, a Johnson & Johnson Company, Adds Important Strengths<br> and Development Capabilities for VX-950 - HCV	View HTML Vertex Pharmaceuticals Reports Second Quarter 2006 Financial Results 303.8 KB
Toggle SummaryJun 30, 2006	Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, Form Collaboration to Develop and Commercialize VX-950 for Treatment of Hepatitis C Vertex Retains all North American Rights Janssen Obtains Exclusive Rights in Europe and Other Regions Vertex to Receive $165 Million Upfront; Tiered Royalty Averaging mid-20 Percent Range Based on Successful Commercialization New Brunswick, NJ and Cambridge, MA, June 30, 2006 -- Vertex HCV	View HTML Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, Form Collaboration to Develop and Commercialize VX-950 for Treatment of Hepatitis C 12.3 KB
Toggle SummaryJun 30, 2006	Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV CAMBRIDGE, Mass. and NEW BRUNSWICK, N.J., June 30 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals General Business	View HTML Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV 12.3 KB
Toggle SummaryMay 23, 2006	Vertex Pharmaceuticals Initiates the First of Two Major Phase II Studies of VX-950 in Treatment-Naïve HCV Patients - PROVE 1 & PROVE 2 Studies Expected to Enroll 580 Patients - HCV	View HTML Vertex Pharmaceuticals Initiates the First of Two Major Phase II Studies of VX-950 in Treatment-Naïve HCV Patients 82.3 KB
Toggle SummaryMay 21, 2006	Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients - 12 of 12 (100%) patients HCV RNA undetectable with no evidence of viral breakthrough at end of 28 days VX-950 dosing -<br /> - 92% (11 of 12) continued to have undetectable HCV RNA through 12 weeks of follow-on therapy - HCV	View HTML Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients 19.5 KB
Toggle SummaryMay 17, 2006	Vertex Pharmaceuticals Initiates Phase I Development for VX-770 in Cystic Fibrosis - FDA Grants Fast Track Designation to VX-770 - Cystic Fibrosis	View HTML Vertex Pharmaceuticals Initiates Phase I Development for VX-770 in Cystic Fibrosis 15.2 KB
Toggle SummaryMay 16, 2006	GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV Research Triangle Park, NC, and Cambridge, MA, May 16, 2006 -- GlaxoSmithKline (GSK) and General Business	View HTML GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV 13 KB
Toggle SummaryMay 11, 2006	Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting - Company Updates Corporate Governance Practices - General Business	View HTML Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting 11.1 KB
Toggle SummaryApr 29, 2006	Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients -New data show that plasma HCV RNA levels were below limit of detection (10 IU/mL) in 8 of 8 patients continued on peg-IFN+RBV for 12 weeks- HCV	View HTML Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients 15.1 KB
Toggle SummaryApr 26, 2006	New Data Highlight Anti-HCV Activity of Investigational Oral Hepatitis C Protease Inhibitor VX-950 Results to be Presented at 41st Annual Meeting of the European Association for the Study of the Liver HCV	View HTML New Data Highlight Anti-HCV Activity of Investigational Oral Hepatitis C Protease Inhibitor VX-950 14.1 KB